Vera Therapeutics, Inc. Class A Common Stock (VERA)
Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company is dedicated to advancing novel biologics targeting specific pathways to address unmet medical needs, aiming to improve patient outcomes in conditions such as kidney diseases and other chronic inflammatory disorders.
Company News
Vera Therapeutics reported a wider net loss of $76.5 million in Q2 2025, with significant progress on its lead drug atacicept for treating Immunoglobulin A Nephropathy (IgAN). The company showed positive clinical trial results and plans to submit a Biologics License Application to the FDA in Q4 2025.
Vera Therapeutics granted stock options and restricted stock units to 15 new employees, with options to purchase 133,500 shares and RSUs for 73,695 shares, vesting over four years.
Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.
The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations. The U.S. economy grew at an annualized rate of 1.3% in the first quarter, marking a downward revision from the previous estimate of 1.6%. The Fed's preferred inflation measure rema...
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.